Oncogenic EGFR signalling networks are being described in glioma and were shown to be both robust and plastic, able to adapt to single molecule inhibition, and these are becoming targets for combination of EGFR and downstream pathway inhibitors [21]. Here, EGFR is linked to central nervous system cancer.